At a glance
ClinicalIndex Comparison RecordN/ACompleted· 52 enrolled
Drug / intervention
Blood drawprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Candidate Gene Polymorphisms and Response to Rituximab-CHOP in Patients With Diffuse Large Cell Lymphoma
In Brief
A clinical study evaluating Blood draw for Lymphoma and Diffuse Large Cell. Completed, enrolled 52 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether people have genes that make them more likely to respond to chemotherapy and/or have side effects from chemotherapy for diffuse large cell lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Diffuse Large Cell
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2005
First PostedJan 2008
Primary CompletionJul 2008
Study CompletionApr 2011
TodayJul 2026
First PostedJan 11, 2008
Enrollment StartFeb 1, 2005
Primary CompletionJul 1, 2008
Study CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 18.5 years ago
Interventions
Blood drawprocedure
Sample Collection for Genotyping prior to cycle 1 treatment of R-CHOP, if patient is enrolled after cycle 1, sample for genotyping should be collected prior to cycle 2.